Chronic muscle pain: How immune cells in the brain drive persistent agony

The hidden drivers of Chronic muscle pain

Researchers have identified a cellular mechanism in the brain that sustains Chronic muscle pain, a discovery long hindered by the difficulty of tracking real-time interactions between neurons and immune cells. The bottom line is a complex cycle: initially hyperactive glutamatergic neurons trigger immune cells in the prefrontal cortex to activate and swarm. These overzealous immune cells then actively prune neural connections, suppressing normal brain activity. This targeted destruction drives both persistent physical aches and associated anxiety.

Moving beyond the spinal cord

For decades, the complex mechanisms maintaining persistent aches remained frustratingly unclear, severely limiting the development of effective therapies. Previous approaches often failed to explain why conditions persist long after local tissues heal.

The current methodology represents a strict departure from those prior limitations. By combining single-cell RNA sequencing with fibre photometry, patch-clamp techniques, and in vivo recordings, scientists can now isolate and manipulate specific cell populations in living animals. This rigorous approach shifts the focus directly to the dorsomedial prefrontal cortex (dmPFC), a brain region associated with processing both sensation and emotion.

Mapping the brain's immune response

The research team used rat models to measure the activity of glutamatergic neurons, which are responsible for excitatory signals in the brain. They observed a fascinating sequence of events: initially hyperactive glutamatergic neurons actually induced the activation, proliferation, and chemotaxis of nearby immune cells.

However, in animals with established persistent pain, these neurons eventually became severely suppressed, demonstrating reduced synaptic plasticity. Single-cell RNA sequencing revealed the exact mechanism behind this ultimate suppression. The researchers measured a marked increase in proinflammatory microglia, the central nervous system's resident immune cells.

These microglia utilised a specific protein, complement receptor 3 (CR3), to essentially consume the synaptic connections between neurons. This synaptic pruning process directly correlated with:

• Reduced neuronal excitability in the dmPFC.
• Increased physical pain responses, known as hyperalgesia.
• Elevated anxiety-like behaviours in the animal models.

When the team inhibited these microglia or knocked down the CR3 protein, the rats' neuronal plasticity recovered. The animals demonstrated a clear, measurable reduction in both pain and anxiety behaviours.

What this means for future treatments

This study suggests that stopping microglial synaptic pruning could offer a distinct therapeutic target for persistent pain. However, we must clearly delineate what this research does not yet solve.

The current findings rely entirely on specific rat models, and human microglial behaviour may differ significantly in a clinical setting. Translating these bench findings into a safe clinical therapy requires developing highly selective drugs that can target this exact microglial-neuron interaction.

Researchers must find a way to stop this pathological pruning in specific brain regions in humans. For now, the study provides a rigorous, vital map of how pain and emotion intertwine at a cellular level.